Taprenepag

Research use only, not for human use.

Taprenepag (CP-544326) is a potent and selective prostaglandin E2 receptor agonist (EC50 = 2.8 nM).

Taprenepag, also known as CP-544326, is a potent and selective EP(2) receptor agonist, was successfully evaluated for its ocular hypotensive activity in a clinical study involving patients with primary open angle glaucoma. Taprenepag is the active metabolite of PF-04217329.(In Vitro):Taprenepag (CP-544326) (0.01-1000 nM) increases cAMP levels in HEK293 cells expressing human EP2 (EC50=2.8 nM). Taprenepag has poor corneal permeability in an ex vivo rabbit corneal model.

Taprenepag (CP-544326) (0.01-1000 nM) increases cAMP levels in HEK293 cells expressing human EP2 (EC50=2.8 nM). Taprenepag has poor corneal permeability in an ex vivo rabbit corneal model.

——

CP-544326 | CP544326,Taprenepag, PF-0421732 metabolite

JAK/STAT Signaling

Pim

PGE2

Others-Field

——

752187-80-7

478.52

C24H22N4O5S

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 64.78 mM

c1cc(cc(c1)OCC(=O)O)CN(Cc1ccc(cc1)n1cccn1)S(=O)(=O)c1cnccc1

2-(3-((N-(4-(1H-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetic acid

(-20℃)

With Ice Pack

≥ 2 years